Process optimization and digital integration strategies to scale cell and gene therapy

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

Process optimization and digital integration strategies to scale cell and gene therapy

Do you want to gain insights into practical strategies for successfully scaling cell and gene therapies that focus on reproducibility, continuity, and cost control?

Attend this webinar to learn how early-stage process optimization directly impacts manufacturing consistency and yield, and how digital systems can be applied to streamline document management, ensure GMP compliance, and improve process efficiency.

The speakers will share real-world case studies illustrating the impact of increasing final yield of advanced cell-based therapies, optimizing batch size, and implementing outsourcing strategies that improve operational performance. As an attendee, you will gain actionable insights into planning logistics, staffing, and scheduling during critical scale-up phases, as well as structuring operations to accelerate timelines and strengthen commercial readiness.

Attend this webinar to:

Learn how early-stage process optimization enhances reproducibility, yield, and cost efficiency
Explore planning, outsourcing, and coordination strategies that drive operational performance
Gain insights into structuring operations and selecting the right CDMO to accelerate product launch
Understand how digital tools support GMP compliance and improve processes

Hélène Negre

Responsible Pharmacist and Pharmaceutical Affairs Director at CELLforCURE by SEQENS

Helene NEGRE, PharmD, PhD, developed her expertise in Cell & Gene Therapy bioproduction through more than 20 years of experience in Advanced Therapy Medicinal Product (ATMPs). Initially, she worked at Pitié-Salpêtrière Hospital (AP-HP) in the Biotherapy department (Pr. Klatzmann). In 2014, she joined Dana Farber Cancer Institute (Boston) and worked for 5 years as technical Director of the Novel Cell therapy team in the Cell Manipulation Core Facility (Pr. Ritz). From 2019 to 2023, she worked at Servier as Scientific Director - Biotechnology and Bioproduction and EFPIA project leader for the IMI program T2Evolve on engineered T cells. She recently joined CELLforCURE by SEQENS as pharmaceutical affairs Director.

Najia Glaserman

Project Management Director at CELLforCURE by Seqens

Najia Glaserman, PharmD, MS, has more than 15 years of experience in the biopharmaceutical industry on biological products (plasma derivatives, monoclonal antibodies transgenic products & ATMPs). Her background includes manufacturing & supply chain oversight, and management of quality assurance within development & commercial areas, with previous roles at Novartis & LFB. She was part of the full CMC development until the marketing approval stage of two biological products acting as QA head. In 2018, she joined the Cell & Gene area for the launch of the 1st approved CAR-T cell in Europe to support hospitals qualification and then moved to one of the production plants to drive Sales & Operation Planning process as well as the supply chain management of the site. She is now Project Director at CELLforCURE by Seqens to lead and execute CMC activities related to ATMP products implementation on site in partnership with clients & commercial team.

Myriam Djemai

Process & Projects Manager at CELLforCURE by Seqens

Myriam Djemai holds a Master’s degree in Cellular and Molecular Biology from Pierre and Marie Curie University. She first joined CELLforCURE in 2015, where she was responsible for the technology transfer of both allogeneic and autologous CAR-T processes. In 2020, she moved to Cellectis as a Bioprocess Engineer, contributing for four years to the development of their allogeneic CAR-T process platform. In March 2025, she decided to return to CELLforCURE by Seqens, taking on the role of Process Development Manager.

Nathalie Lelot

Chief Operating Officer at CELLforCURE by Seqens

Nathalie Lelot, MSc, built her expertise in pharmaceutical production operations through more than 15 years of experience in the pharmaceutical industry. She started her career at LFB as Deputy Production Manager before joining Novartis as Production Unit Head. Throughout these roles, she developed strong skills in driving continuous improvement of production, quality, and operational processes to maintain performance, competitiveness, and compliance. Nathalie holds a Master’s degree in Pharmaceutical Biotechnologies with a specialization in Advanced Therapy Medicinal Products (ATMPs). In 2024, she is now Chief Operating Officer at CELLforCURE by Seqens.

You have registered for this webinar